Patents by Inventor Bianka Prinz

Bianka Prinz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human PD-L2 antibodies and methods of use therefor
    Patent number: 11976128
    Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: May 7, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael A. Curran, Ashvin R. Jaiswal, Dongxing Zha, Kui Voo, Carlo Toniatti, Bianka Prinz, Nadthakarn Boland
  • Antibody variable domains targeting the NKG2D receptor
    Patent number: 11939384
    Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: March 26, 2024
    Assignee: Dragonfly Therapeutics, Inc.
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • CD38 MODULATING ANTIBODY
    Publication number: 20240092928
    Abstract: The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: September 1, 2023
    Publication date: March 21, 2024
    Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
  • ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR
    Publication number: 20240076384
    Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
    Type: Application
    Filed: November 3, 2023
    Publication date: March 7, 2024
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR
    Publication number: 20240076385
    Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
    Type: Application
    Filed: November 3, 2023
    Publication date: March 7, 2024
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR
    Publication number: 20240067735
    Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
    Type: Application
    Filed: November 3, 2023
    Publication date: February 29, 2024
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • HUMAN PD-L1 ANTIBODIES AND METHODS OF USE THEREFOR
    Publication number: 20240043538
    Abstract: The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.
    Type: Application
    Filed: November 17, 2022
    Publication date: February 8, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventors: Michael A. CURRAN, Carlo TONIATTI, Ashvin R. JAISWAL, Dongxing ZHA, Kui VOO, Bianka PRINZ, Nadthakarn BOLAND
  • Antibody variable domains targeting the NKG2D receptor
    Patent number: 11884733
    Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: January 30, 2024
    Assignee: Dragonfly Therapeutics, Inc.
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • Proteins binding HER2, NKG2D and CD16
    Patent number: 11884732
    Abstract: Multi-specific binding proteins that bind HER2, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: January 30, 2024
    Assignee: Dragonfly Therapeutics, Inc.
    Inventors: Gregory P. Chang, Ann F. Cheung, William Haney, Bradley M. Lunde, Bianka Prinz
  • PROTEINS BINDING CD123, NKG2D AND CD16
    Publication number: 20240018266
    Abstract: Multi-specific binding proteins that bind CD123, the NKG2D receptor, and CD16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: April 21, 2023
    Publication date: January 18, 2024
    Inventors: Gregory P. Chang, Ann F. Cheung, William Haney, Bradley M. Lunde, Bianka Prinz
  • MULTISPECIFIC BINDING PROTEINS TARGETING CEA
    Publication number: 20230391877
    Abstract: Multi-specific binding proteins that bind the NKG2D receptor, CD16, and a tumor-associated antigen selected from carbonic anhydrase 9 (CAIX), anoctamin-1 (ANO1), mesothelin, TROP2, CEA and claudin-18.2 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: February 8, 2023
    Publication date: December 7, 2023
    Inventors: Gregory P. Chang, Ann F. Cheung, William Haney, Bradley M. Lunde, Bianka Prinz
  • Anti-CD25 for tumour specific cell depletion
    Patent number: 11814434
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-672 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: PHATFKAMA YKEGTM (42-56) and YQCVQGYRALH (150-160) on CD25. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: November 14, 2023
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, James Geoghegan, Bianka Prinz, Sergio Quezada
  • PROTEINS BINDING NKG2D, CD16 AND NECTIN4
    Publication number: 20230357409
    Abstract: Multi-specific binding proteins that bind the NKG2D receptor, CD16, and a tumor-associated antigen are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: February 13, 2023
    Publication date: November 9, 2023
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • Anti-CD25 antibody agents
    Patent number: 11802160
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: October 31, 2023
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • Anti-CD25 for tumour specific cell depletion
    Patent number: 11802161
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-634 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: October 31, 2023
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, James Geoghegan, Bianka Prinz, Sergio Quezada
  • Anti-CD25 antibody agents
    Patent number: 11787866
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: October 17, 2023
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • CD38 modulating antibody
    Patent number: 11780930
    Abstract: The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: October 10, 2023
    Assignee: BLACK BELT THERAPEUTICS LIMITED
    Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
  • COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
    Publication number: 20230303702
    Abstract: Combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.
    Type: Application
    Filed: January 4, 2023
    Publication date: September 28, 2023
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, Eva Gutierrez, William Haney, Bradley M. Lunde, Nicolai Wagtmann, Bianka Prinz
  • ANTI-COAGULATION FACTOR XI ANTIBODIES
    Publication number: 20230287141
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Application
    Filed: April 18, 2023
    Publication date: September 14, 2023
    Applicants: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz, Vaishnavi Ganti, Mohammad Tabrizifard
  • MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF
    Publication number: 20230265197
    Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Application
    Filed: October 26, 2022
    Publication date: August 24, 2023
    Inventors: Natalya D. BODYAK, Michael J. DEVIT, Eric M. KRAULAND, Timothy B. LOWINGER, Peter U. PARK, Bianka PRINZ, Aleksandr V. YURKOVETSKIY